By Ted Bosworth
Philadelphia—The multitarget stool DNA test was approved in 2014 for patients with an average risk for colorectal cancer, but new data support expanding its applications to include surveillance of high-risk patients between colonoscopies.
The analyses were based on a large series of cases collected by investigators at Mayo Clinic with the test, MT-sDNA (Cologuard, Exact Sciences). The test shows promise for interval screening between colonoscopies because it has a similar